4//SEC Filing
Silver Gabrielle Alison 4
Accession 0001385508-21-000045
CIK 0001385508other
Filed
Mar 16, 8:00 PM ET
Accepted
Mar 17, 4:51 PM ET
Size
20.0 KB
Accession
0001385508-21-000045
Insider Transaction Report
Form 4
Silver Gabrielle Alison
Director
Transactions
- Sale
Common Stock
2021-03-15$11.64/sh−3,900$45,396→ 15,467 total - Exercise/Conversion
Common Stock
2021-03-16$10.00/sh+2,231$22,310→ 17,698 total - Exercise/Conversion
Stock Option (right to buy)
2021-03-15$10.00/sh−4,518$45,180→ 10,482 totalExercise: $10.00Exp: 2021-05-16→ Common Stock (4,518 underlying) - Exercise/Conversion
Stock Option (right to buy)
2021-03-16$10.00/sh−2,231$22,310→ 8,251 totalExercise: $10.00Exp: 2021-05-16→ Common Stock (2,231 underlying) - Sale
Common Stock
2021-03-17$11.07/sh−7,157$79,228→ 16,478 total - Exercise/Conversion
Stock Option (right to buy)
2021-03-17$10.00/sh−7,886$78,860→ 365 totalExercise: $10.00Exp: 2021-05-16→ Common Stock (7,886 underlying) - Exercise/Conversion
Common Stock
2021-03-15$10.00/sh+4,518$45,180→ 19,367 total - Sale
Common Stock
2021-03-16$11.50/sh−1,949$22,414→ 15,749 total - Exercise/Conversion
Common Stock
2021-03-17$10.00/sh+7,886$78,860→ 23,635 total
Footnotes (6)
- [F1]The shares were sold to cover the $10 exercise price of the 4,518 vested stock options. The net shares of 618, after selling to cover the exercise price, will be held by the Reporting Person.
- [F2]This transaction was executed in multiple trades at prices ranging from $11.60 to $11.78. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]The shares were sold to cover the $10 exercise price of the 2,231 vested stock options. The net shares of 282, after selling to cover the exercise price, will be held by the Reporting Person.
- [F4]The shares were sold to cover the $10 exercise price of the 7,886 vested stock options. The net shares of 729, after selling to cover the exercise price, will be held by the Reporting Person.
- [F5]This transaction was executed in multiple trades at prices ranging from $11.00 to $11.30. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F6]On May 17, 2016, the reporting person was granted an option to purchase 35,000 shares of Common Stock. The options vest as follows: (i) 11,667 share upon the up listing of the Issuer to The NASDAQ Stock Market (which occurred on August 29, 2017); (ii) 11,667 shares upon the cumulative funding of the Issuer in excess of $5,000,000 by institutional investors, commencing May 5, 2016 (which performance criteria was met on December 13, 2016); and (iii) 11,666 shares upon the first submission of a New Drug Application ("NDA") to the FDA for one of Issuer's products by either the Issuer or an Issuer licensee.
Documents
Issuer
OPIANT PHARMACEUTICALS, INC.
CIK 0001385508
Entity typeother
Related Parties
1- filerCIK 0001685532
Filing Metadata
- Form type
- 4
- Filed
- Mar 16, 8:00 PM ET
- Accepted
- Mar 17, 4:51 PM ET
- Size
- 20.0 KB